Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Celgene’s Global Revlimid Sales Total $2.47 Billion In 2010 – Up 45%

Home/Celgene’s Global Revlimid Sales Total $2.47 Billion In 2010 – Up 45%

Celgene’s Global Revlimid Sales Total $2.47 Billion In 2010 – Up 45%

Celgene Corporation, makers of the oral, anti-myeloma chemotherapy agent, Revlimid, announced their 4th quarter and full-year financials this morning.

I’m not going to post all of the data here.  But several parts of the report should interest my fellow multiple myeloma patients:

For the 4th quarter, Total Revenue Increased 38 Percent to $1.07 Billion
Global REVLIMID® Net Product Sales Increased 42 Percent to $708 Million
Global THALOMID® Net Product Sales of $91 Million

Here are figures for all four quarters of 2010:

Total Revenue Increased 34 Percent to $3.60 Billion
Global REVLIMID Net Product Sales Increased 45 Percent to $2.47 Billion
Global THALOMID Net Product Sales of $387 Million

That’s a lot of money!   All I know is I’m a good customer–my insurance company paid over $84,000 for my Revlimid this year.  Add in my co-pays and deductible of close to $2,000 and we can all agreed I did my part to support Celgene’s bottom line.
 
Do I think that is way too much to pay for my medication?  Yes!  But I’m alive and relatively well.  Thanks Cigna!  I paid my health insurance premiums and you stepped-up and paid as promised.  Thanks, Celgene!  Revlimid helped keep me alive for another year.
 
Enough said for now.  Feel good and keep smiling!  Pat